Muna Therapeutics Announces Strategic Alliance with GSK to Advance Alzheimer’s Research

Copenaghen (Denmark) – Muna Therapeutics ApS, a Golgi Neuroscience’s portfolio company developing therapies that slow or stop devastating neurodegenerative diseases, has achieved a major milestone by forming a strategic alliance with GSK. This multi-year collaboration aims to slow or halt the progression of Alzheimer’s and other neurodegenerative diseases by leveraging Muna’s cutting-edge all-in-human MiND-MAP spatial multi-omics approach.

As part of the agreement, Muna will receive an upfront payment of €33.5 million and is eligible for up to €140 million per target in milestone payments. This partnership highlights Muna’s innovative focus on resilience biology to combat neurodegeneration and represents a significant step forward in developing transformative treatments for diseases like Alzheimer’s.

For more details, please go to the Muna Website or the Golgi Neurosciences’ Linkedin Page